May. 15, 2008
CA, Eurekify Team to Provide Faster Time-to-Value in Identity Management Deployments.

http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20080514005644&newsLang=en

Mar. 18, 2008
Cellvine Ltd. Signs Distribution Agreement with Tessco Technologies Inc.

Cellvine Ltd., recently announced that it has signed a distribution agreement with Tessco Technologies Incorporated (Nasdaq:TESS). Tessco, a US based provider of integrated product and supply chain solutions to the professionals that design, build, run, maintain and use wireless mobile, fixed and in-building systems. The Company links customers with integrated product and supply chain solutions configured from product choices made by world-class manufacturers. As part of the agreement, Tessco will range & sell Cellvine's In-Building Amplifiers & Repeaters.

Cellvine Ltd. offers a broad range of cellular coverage enhancement products and solutions based on the company's exclusive technology for improving cellular signals for in-building, urban and rural over-ground and subterranean environments such as mines and tunnels. Cellvine's Comprehensive coverage management tools provide operators with full real-time control of their coverage networks without the need for costly infrastructure replacement.

Mar. 18, 2008
Apexum Ltd. Completes Recruitment and Treatment of 100 Clinical Study Patients.

Apexum Ltd. has developed a family of miniature, minimally invasive surgical tools, facilitating highly innovative methods for the treatment of Periapical Lesions, associated with root canal infections.

The core technology of the company allows the removal of the lesion in a minimally invasive fashion, achieving faster healing kinetics and better healing rate than standard root canal treatment, without the need for a costly and complicated apicoectomy operation.

In Accordance with FDA Requirements, the company recently completed recruitment and treatment of 100 clinical study patients. Interim results from 54 patients with 3 month follow up and 41 patients with 6 months follow up, show a substantial improvement in both healing kinetics and the healing rate of Periapical Lesions compared with traditional root canal treatments. Results for 3 months follow up indicate that there was a 96% healing rate experienced at the study group compared to 32% in the control group. Results for 6 month follow up indicate similar positive results, with a 95% healing rate experienced at the study group compared to 41% in the control group.

Upon the successful completion of the trial Apexum will apply to FDA for approval of the device.

Mar. 18, 2008
Visionsense Corp. Announces FDA 510 (K) Clearance for New VSII System.

Visionsense Announces FDA 510(k) Clearance for VSII - Visionsense Stereoscopic Vision System

ORANGEBURG, N.Y., March 18 /PRNewswire/ -- Visionsense Corp. announces FDA 510(k) Clearance of the new VSII -- Visionsense Stereoscopic Vision System. The system is based on a miniature 3.4 mm distal ("chip-on-a-stick") stereoscopic 3D camera targeting Minimal Invasive laparoscopic and endoscopic Surgery (MIS).

Visionsense's stereoscopic 3D camera enables and enhances MIS surgical procedures that are under served by traditional 2D visualization, in markets such as: Spine, Neurosurgery, Orthopedics, Endoscopy, General Surgery, GYN, Robotics, and others.

The company has licensed the technology to various strategic marketing partners, expecting launches later this year.

About Visionsense Corp.

Visionsense exclusively licenses its technology, application or segment specific, to strategic partners, benefiting a unique competitive advantage. The Company develops and manufactures customized Miniature Stereoscopic 3D cameras/sensors that enable surgeons to see "natural" Stereovision, thus enhancing image understanding and hand-eye coordination. These re-useable or disposable cameras are distally assembled on the tip of a flexible / rigid scope or instrument. The technology further assists the surgeon by providing advanced software features, such as image fusion (combining stereovision with MRI, CT or ultrasound for real-time "see-through-tissue") and 3D measurements.

Jan. 30, 2008
B-Balloon Ltd & Neovasc Medical Ltd to Merge with Medical Ventures Corp. (TSXV: MEV).

January 30, 2008 – Or-Yehuda, Israel – B-Balloon Ltd and Neovasc Medical Ltd., both portfolio cardio-vascular companies incubated by Peregrine Ventures and Incentive (Peregrine's Technological Incubator), are to merge with Medical Ventures Corp. (TSXV: MEV). The merger, announced today on the signing of an agreement is intended to establish a leading Cardio-Vascular company, headed by an exceptionally experienced team.

Both B-Balloon Ltd. & Neovasc Medical Ltd. are focused on developing new technologies for the interventional treatment of heart and vascular diseases. B-Balloon is developing devices used to treat ostial and bifurcation lesions in coronary and peripheral arteries, and Neovasc has developed a specialized stent for the treatment of refractory angina. Medical Ventures, is a devices company specializing in products for the vascular and surgical markets.

Supporting the merger, as a shareholder of the companies and financier of the new company is U.S. pharmaceutical entrepreneur Phillip Frost, MD. Dr. Frost, chair of Peregrine Ventures' Investment Committee, is also the former CEO and a principal shareholder of IVAX Corporation, which was acquired in 2006 by Teva Pharmaceutical Industries for $9.9 billion (US).

Subject to all the closing conditions being met, the companies are targeting completion in approximately 90 days. All details relevant to the merger including final shareholdings will be available at the time of final closing of the agreement.

On completion of the transactions, B-Balloon and Neovasc's product development activities will continue in Israel, while Medical Ventures' head office will remain in Canada. Both Neovasc and B-balloon will add two nominees to a revamped, seven-person Medical Ventures board. Board nominees will be named prior to Closing. Eyal Sandach, B-Balloon's current CEO will manage the Israel facilities, Alexei Marko, currently Medical Ventures' president and chief operating officer, will assume the role of president and CEO. Paul Geyer will remain as chairman of the board and Chris Clark will remain as CFO.

Commenting on the merger plans, Dr. Frost said: “Each of these companies has compelling proprietary technologies with significant clinical potential. Together, they offer expansive treatment options for the vascular disease market. We are excited by the plans to take each product forward to commercialization, and we also see the potential for future strategic partnerships to grow Medical Ventures' market presence and shareholder value.”

Alexei Marko, incoming CEO, added: “Acquiring Neovasc and B-Balloon will bring several new vascular therapies into Medical Ventures' product pipeline and will provide us with attractive short- and long-term revenue opportunities. In securing the support of the Frost Group and Peregrine Ventures, we have partnered with a team that has priority access to new life-sciences technologies worldwide, as well as to the capital we need as we accelerate our move into the U.S. and other markets.”

About the Participating Companies:

B-Balloon

B-Balloon is developing unique stents and stent delivery systems being designed to allow the quick and safe percutaneous placement of stents in bifurcation and ostial lesions. Ostial and bifurcation lesions are considered two of the major unresolved challenges in percutaneus coronary and peripheral artery intervention.

See http://www.peregrinevc.com/portfolio_company.asp?ID=4 .

Neovasc

Neovasc is developing a breakthrough, minimally invasive treatment for patients of Ischemic Heart Disease (IHD) who are not treatable by existing medical procedures. IHD is caused by limited inflow of blood in the coronary arteries. Using a proprietary device called the Reducer™, Neovasc's treatment is designed to increase the blood flow to territories of the heart suffering from decreased perfusion and improve cardiovascular function. See http://www.peregrinevc.com/portfolio_company.asp?ID=5 .

Medical Ventures Corp.

Medical Ventures Corp. develops, manufactures and markets medical devices for the quickly growing vascular and surgical marketplace. MEV products help doctors treat a wide range of health concerns, including vascular disease and obesity. MEV products include the Metricath® arterial and in-stent measurement system and PeriPatch™, a line of surgical tissue and staple line reinforcement products. Medical Ventures is also a contract medical devices manufacturer. For more information, please visit: http://www.medical-ventures.com

Jan. 18, 2008
B-Balloon Ltd., Neovasc Medical Ltd. & Neurosonix Ltd. Feature in CardioVascular Device & Drugs Publication.

http://www.peregrinevc.com/cms/upload/Israeli Cardio Vascular Device Companies Edited Version.pdf

Jan. 8, 2008
Eurekify Doubles Revenue For the Fourth Year in a Row.

Tuesday, January 8, 2008 , 9:00 am Eastern Time Press Release

Eurekify Doubles Revenue For the Fourth Year in a Row

Tel Aviv, Israel - January 8, 2008 - Eurekify, the pioneer and leading provider of comprehensive, cohesive, and effective solutions for the management of Privileges, Roles, and Policies, is pleased to announce a fourth record year of revenue and profits. Eurekify's year-to-year revenue doubled in 2007, reflecting a growing adoption of role & compliance management solutions.

Eurekify founded the role & compliance management space in 2002, introducing novel pattern recognition technology that eases and speeds development and deployment of role & compliance models. Since then, Eurekify has evolved and matured its solutions in cooperation with customers and partners. Today, Eurekify offers the only solution that is comprehensively broad and deep, and cohesively integrates

Cleanup, and ongoing management of fine granularity privileges on any target system and application role modeling, and ongoing model management and role administration business processes compliance modeling, and ongoing governance, risk, and compliance processes

All in all, Eurekify's Enterprise Role & Compliance Manager (ER&CM) helps organizations assess their Identity Management (IdM) needs, and deploy a business oriented role-based solution that maximizes security, manageability, and compliance. Eurekify Sage is unique in its capabilities and is regularly recommended by leading IdM implementers worldwide.

“In 2007, we find customers increasingly adopting role & compliance management solutions”, says Azi Cohen, Eurekify CEO, “Analysts and solution integrators are now increasingly recommending that customers cleanup privileges and deploy role management solutions ahead of or in parallel to IdM deployment. This best practice increases success rate of IdM deployment as a whole, and results in business-oriented solutions where 80% of access rights are managed according to business needs and practices. Eurekify's pattern recognition technology is the key to practical and more cost effective deployments.”

About Eurekify:

Eurekify is the leading provider of comprehensive, cohesive, and effective Privileges, Roles, and Policy Management solutions. Eurekify's Enterprise Role & Compliance Manager (ER&CM) helps organizations assess their Identity Management (IdM) needs, and deploy a business oriented role-based solution that maximizes security, manageability, and compliance. Based on its advanced Sage pattern recognition technology, Eurekify solutions ease and speed role modeling, compliance modeling, and the ongoing management of a role & compliance management solution. Eurekify Sage is unique in its capabilities and is regularly recommended by leading IdM implementers worldwide.

Dec. 14, 2007
Neurosonix Ltd. Announces Receipt of CE Mark Certificate and ISO Certification for the EmBlocker, V2.

Neurosonix Ltd. announced today that the company has received the certificate for CE marking of conformity for the EmBlockerTM V2 and ISO 13485:2003 certification.

NeuroSonix Ltd. is developing non-invasive embolic protection devices for use in cardiac surgery and cath-lab practice for the prevention of Acute Cerebral Embolism. Acute Cerebral Embolism is considered a major source of neurological dysfunction following cardiac surgery and other invasive and minimally invasive procedures.

The company's proprietary technology is based on utilizing acoustic forces to manipulate embolic material flowing inside arteries, deflecting it away from vessels supplying blood to harmful locations such as the brain. The technology is efficacious against embolic material composed of solid particles as well as gaseous bubbles.

Neurosonix's first product, the Emblocker™ is intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The second product, The Protection Collar, is intended to provide embolic protection during minimally-invasive procedures and Cath-lab practice.

Oct. 31, 2007
Cellvine Ltd. Opens Up Ukraine Market with First Sales.

Cellvine, a leading developer and provider of coverage enhancement solutions for cellular networks, announced during quarter 3, 2007 that it has successfully secured its first sales in the Ukraine market.

Oct. 10, 2007
Prestigious EACTS Award Granted to Israeli Company Neurosonix.

Thanks to developing EmBlocker device, Israeli medical device company NeuroSonix Ltd. received a European recognition for the research in thoracic and cardiovascular fields.

Expected in Europe for 2008, the new product demonstrated an important improvement in cerebral embolism, a major cause of brain damage during cardiac surgical procedures. EmBlocker diminished an emboli flow to the brain by record 65%.

Created in 2002, NeuroSonix Ltd. is backed up by such top investors as Peregrine Ventures, Elron Electronic Industries, Evergreen Venture Partners, Ofer Hitech, Yozma Group and D Partners.

About EACTS

Founded in 2000, The European Association of Cardio-Thoracic Surgery (EACTS), seeks to advance education in the field of cardiovascular and thoracic surgery, to promote for the public benefit research in thoracic physiology, pathology and therapy and to correlate and disseminate the useful results thereof.

Oct. 1, 2007
TNK-BP Selects Geomage 3D Multifocusing Technology for West Siberian Project.

Geomage Ltd, the developer of MultiFocusing Technology, announces that TNK-BP, one of world's largest privately owned crude oil production companies, has chosen to begin processing their West Siberia oilfield seismic data using Geomage's newest 3D seismic data processing technology.

MultiFocusing provides a significant advantage to TNK-BP, a leading Russian oil company, in their efforts to pinpoint reserves. Geomage will provide TNK-BP with a migrated cube of amplitudes and velocities in time scale. The TNK-BP agreement gives significant market visibility to Geomage in Russia and demonstrates critical improvements over current seismic data processing methods.

"We believe that 3D MultiFocusing can provide considerably more reliable seismic images necessary to identify potentially lucrative oil & gas reserves," said Randy Peters, Project Manager at Russkoye Development, a branch of TNK-BP. “Geomage's images and their geophysical processing expertise has proven a significant increase in signal-to-noise ratio and resolution, clearly higher than any other seismic data processing output we have found on the market.”

While Geomage has recently enjoyed widespread recognition of its 2D seismic imaging throughout the world, the TNK-BP project will be the first time MultiFocusing is used for 3D data processing. Oil exploration companies of all sizes will now have access to highly accurate seismic images, for any geological conditions, in order to accurately explore oil and gas reserves. “We are proud that TNK-BP, the leading Russian oil company, has chosen to pioneer oil exploration using our unique 3D seismic imaging for their important project,” said Emil Guberman, a Geomage founder and VP Marketing & Sales.

“Together, we will validate the effectiveness of 3D MultiFocusing by identifying valuable reserves and clearly reducing exploration and production costs.”

Jul. 30, 2007
Apexum complete pre-clinical study with outstanding results.

Final results from Apexum's pre-clinical study show a substantial improvement in both healing kinetics and healing rate of Periapical lesions, compared to conventional root canal treatment – after 6 months there was a 95% healing rate experienced at the study group compared to 61% in the control group. Initial results from clinical studies show the same level of improvement, with 92% healing at 3 months, compared to 46% at the control group. Apexum is developing a family of miniature, minimally invasive dental surgical tools, facilitating highly innovative methods for the treatment of Periapical Lesions, associated with root canal infections.The core technology of the company will allow the removal of the lesion in a minimally invasive fashion, achieving faster healing kinetics and a better healing rate than standard root canal treatment, without the need for a costly and complicated Apicoectomy operations.

Jul. 2, 2007
Valtech's 1st animal trial deemed a success!

Valtech conducted its first animal trial yesterday, July the 2nd 2007. The trial tested the percutaneous insertion of the Annuloplasty ring valve and was deemed a success.

Jun. 19, 2007
Peregrine Ventures invests in CardioNova

Atrial fibrillation is a disorder found in about 2.2 million Americans. Atrial Fibrillation causes more than 70,000 strokes each year in the U.S., where 160,000 new cases of Atrial Fibrillation are diagnosed each year.The biggest problem with AF management today is the lack of treatment options that are both highly effective and safe. Peregrine Ventures new Portfolio company, CardioNova offers a cutting edge technology that will allow the use of the gold standard procedure Cox-maze (for Atrial Fibrillation treatment) via a percutaneous procedure.

Jun. 11, 2007
Cellvine Introduces SDAS - Smart Distributed Antenna System For High Quality Cellular Coverage.

http://www.peregrinevc.com/cms/upload/Cellvine introduces SDAS.pdf

Jun. 11, 2007
Cellvine Begins Commercial Deployment of Its Coverage Enhancement Solutions at Leading Vietnamese Operator.

http://www.peregrinevc.com/cms/upload/Cellvine Begins Commercial Deployment Of Its Coverage Enhancement Solutions.Vietnamese GSM Operator.pdf

Jun. 6, 2007
Dr. Avi Molcho, Former Managing Director, Lifescience, Giza Venture Capital appointed CEO of Neovasc Ltd

In Q2 2007, Dr. Avi Molcho was appointed the new CEO of Neovasc. Dr. Avi Molcho is the former Managing Director, Lifescience, Giza Venture Capital and brings with him a great deal of experience and expertise in the Life Science sector, as well as a strong understanding of Life Science investments.

Jun. 6, 2007
Valtech wins RAD BIO MED Entrepreneurs Prize for "Outstanding Project 2006/2007"

On 6th June 2007 at the ILSI BIO MED Conference in T.A organized by the Israel Life Science Industry, Valtech was selected out of 100 other promising companies as the recipient of the RAD BIO MED Entrepreneurs Prize for "Outstanding Project 2006/2007". Accepting the award on behalf of the company was its founder & CEO, Amir Gross. Valtech is developing Percutaneous Annuloplasty ring valve repair for the treatment of Mitral Valve Regurgitation. Using a simple catheterization process for implementing the device which treats Mitral Valve Regurgitation, Valtech's treatment will be an alternative to the invasive open heart procedures that are currently in use today. For more information please click on Valtech in the Portfolio Companies section.

Jun. 5, 2007
Eurekify nominated One of Top 5 Security Companies at IDC IT Security Road Show 2007

http://www.peregrinevc.com/cms/upload/Eurekify nominated One of Top 5 Security Companies IDC IT Sec Road show 2007.doc